Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas
about
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the StoryInhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantroneActivated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft modelsTargeting protein kinases to reverse multidrug resistance in sarcoma.Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein.The flip side of doxorubicin: Inflammatory and tumor promoting cytokines.The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin.
P2860
Q26742078-F5FB6BF3-825B-4292-B1AC-2F09CA7130CBQ27313997-292C4A5A-AAE4-48E2-BD98-B781A61A05CEQ28484919-575E53EB-64FF-40F8-A3A6-20B0D5304B03Q34036124-E7B2420D-D6A8-4D10-B48C-1D06198061C2Q34628255-FED54FC2-02CD-4338-ABBB-E914AC399D4AQ35171274-241E6AE2-C0D9-4B4C-B1CF-AC78FC1DF0B6Q36442931-1EDA8195-37CC-45F6-889D-F85C2DF4523DQ36527950-9D7A3D09-94A2-4F40-A4F2-F01157E8AFF7Q36591937-5175CFE2-91D8-46B2-B14A-0EA0DD87269AQ38261599-4FBA60D0-F397-433C-BFB2-D96093D1BD8DQ38773607-91457B0A-DF8F-46D6-B231-3BD4AECA12B4Q38842538-151A667E-5437-4A23-93E9-8B498BE176D6Q39031326-399BD1E7-6504-4E36-88AB-30E27936E889Q41854202-CB4A189C-6539-4794-9920-F2DB81B22FB6Q41905184-B8C9AAED-7A7C-4E6A-9A92-D3372B9497A1Q47385759-A577A16C-9EF3-4059-9E58-67C91D2763A8Q53038645-08482672-9862-44D3-991F-C9662913F2FB
P2860
Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@ast
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@en
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@nl
type
label
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@ast
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@en
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@nl
prefLabel
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@ast
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@en
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@nl
P2093
P2860
P3181
P1433
P1476
Nilotinib counteracts P-glycop ...... ubicin in soft tissue sarcomas
@en
P2093
Antonio Gutiérrez
Javier Martín-Broto
Jordi Martínez-Serra
Oliver Vögler
Rafael Ramos
Regina Alemany
Victor Hugo Villar
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0037735
P407
P577
2012-01-01T00:00:00Z